Rationale for SOX Chemotherapy Backbone in ASTRUM-006 Trial
The ASTRUM-006 trial selected SOX (S-1 plus oxaliplatin) as the chemotherapy backbone because it represents an established, effective, and well-tolerated standard regimen for locally advanced gastric cancer in Asian populations, with proven efficacy in both perioperative and adjuvant settings.
Evidence-Based Selection of SOX
Established Efficacy in Asian Populations
The SOX regimen was chosen based on robust phase III evidence demonstrating its effectiveness specifically in Asian patients with gastric cancer:
- S-1 has proven superiority in Asian populations: The SPIRITS trial established S-1 plus cisplatin as superior to S-1 monotherapy, with median OS of 13 vs 11 months 1
- Oxaliplatin-based regimens show comparable efficacy to cisplatin: Multiple trials (REAL-2, ML17032) demonstrated that oxaliplatin is as effective as cisplatin in gastroesophageal cancer 1, 2, 1
- SOX specifically validated in Asian trials: The SOPP trial (phase III) confirmed SOX was non-inferior to S-1 plus cisplatin in metastatic/recurrent gastric cancer, with median PFS of 5.6 vs 5.7 months 3
Superior Safety Profile
Oxaliplatin offers significant toxicity advantages over cisplatin, which is critical for perioperative treatment where patients must tolerate both neoadjuvant and adjuvant therapy:
- Reduced severe toxicities: Compared to cisplatin, oxaliplatin causes lower rates of grade 3-4 neutropenia, alopecia, renal toxicity, and thromboembolism 1
- No nephrotoxicity concerns: Oxaliplatin eliminates the need for aggressive hydration protocols required with cisplatin 2
- Better tolerability in elderly patients: FLO (fluorouracil, leucovorin, oxaliplatin) showed superior outcomes in patients >65 years compared to cisplatin-based regimens 1
Perioperative Setting Validation
The SOX regimen had specific evidence supporting its use in the perioperative context before ASTRUM-006:
- RESOLVE trial demonstrated perioperative SOX efficacy: This phase III trial showed perioperative SOX significantly improved 3-year disease-free survival (HR 0.77) compared to adjuvant capecitabine plus oxaliplatin in locally advanced gastric cancer 4, 5
- Adjuvant SOX approval in Japan: Following J-CLASSIC and SOX-adjuvant trials, S-1 plus oxaliplatin was approved as an adjuvant regimen 6
- Feasibility in neoadjuvant setting: Phase I/II studies confirmed SOX could be safely administered preoperatively with acceptable toxicity and promising pathological response rates 7
Practical Advantages for Trial Design
Convenience and Compliance
- Oral S-1 administration: Unlike infusional 5-FU, S-1 is taken orally, improving patient convenience and reducing central line complications 1
- Simplified administration: The 3-week cycle (oxaliplatin day 1, S-1 days 1-14) is straightforward and well-established 3, 8
- No hospitalization required: Outpatient administration feasible for most cycles
Regional Appropriateness
S-1 is particularly suited for Asian populations where ASTRUM-006 was conducted (China and Thailand):
- S-1 is widely available and approved in Asian countries 6
- Pharmacogenetic differences make S-1 better tolerated in Asian vs. non-Asian populations 9, 10
- Extensive Asian experience with S-1-based regimens provides robust safety data 6
Alternative Regimens Considered
While other perioperative regimens exist, SOX offered specific advantages for this trial:
FLOT (5-FU, leucovorin, oxaliplatin, docetaxel): Though FLOT showed superior outcomes in Western populations, it has significantly higher toxicity (48% requiring dose adjustments in elderly patients) 4. The addition of taxanes increases neutropenia, stomatitis, and nausea without clear survival benefit in Asian populations 10
Capecitabine plus oxaliplatin (CapOx): While effective, the RESOLVE trial directly demonstrated SOX superiority over CapOx in the adjuvant setting 5
Cisplatin-based regimens: Higher toxicity profile makes them less suitable for perioperative treatment where cumulative toxicity is a concern 1, 2
Critical Considerations
The SOX backbone allowed ASTRUM-006 to isolate the immunotherapy effect: By using a well-established, effective chemotherapy regimen with known toxicity profiles, the trial could clearly attribute any additional benefit to serplulimab rather than variations in chemotherapy efficacy 8.
Common pitfall to avoid: Do not assume Western perioperative regimens (like FLOT) are automatically superior in Asian populations. Regional pharmacogenetic differences, drug availability, and population-specific efficacy data must guide regimen selection 6, 10.
The final RESOLVE trial data confirmed this choice was appropriate, showing 5-year OS of 60% with perioperative SOX, validating it as a standard treatment for locally advanced gastric cancer in Asian patients 5.